ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2018
Characterization of 3 Novel Tau Radiopharmaceuticals,
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 47 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
11.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.
- Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade.International journal of molecular sciences · 2022Pooled it
- Evaluation of [Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021Trial
- DynamicalbioRxiv : the preprint server for biology · 2026Article
- Synthesis and Evaluation of Radioiodinated [Journal of labelled compounds & radiopharmaceuticals · 2026Article
- Human biodistribution and radiation dosimetry of two novel α-synuclein PET tracers,Scientific reports · 2025Article
- Strategies of positron emission tomography (PET) tracer development for imaging of tau and α-synuclein in neurodegenerative disorders.RSC medicinal chemistry · 2025Review
- Establishing tau-PET cut-points for cognitive diagnosis withImaging neuroscience (Cambridge, Mass.) · 2025Article
- Radioiodinated Tau Imaging Agent III Molecular Modeling, Synthesis, and Evaluation of a New Tau Imaging Agent, [Molecules (Basel, Switzerland) · 2024Article
- Article
- Tau: a biomarker of Huntington's disease.Molecular psychiatry · 2023Review
- Tau positron emission tomography in patients with cognitive impairment and suspected Alzheimer's disease.Fukushima journal of medical science · 2023Article
- The Use of Tau PET to Stage Alzheimer Disease According to the Braak Staging Framework.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Review
- The Sensitivity of Tau Tracers for the Discrimination of Alzheimer's Disease Patients and Healthy Controls by PET.Biomolecules · 2023Review
- PET molecular imaging for pathophysiological visualization in Alzheimer's disease.European journal of nuclear medicine and molecular imaging · 2023Review
- Recent Developments in Carbon-11 Chemistry and Applications for First-In-Human PET Studies.Molecules (Basel, Switzerland) · 2023Review
- Alzheimer's Dementia: The Emerging Role of Positron Emission Tomography.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2022Review
- Tracers progress for positron emission tomography imaging of glial-related disease.Journal of biomedical research · 2022Article
- PET Imaging in Animal Models of Alzheimer's Disease.Frontiers in neuroscience · 2022Review
- GC-CNNnet: Diagnosis of Alzheimer's Disease with PET Images Using Genetic and Convolutional Neural Network.Computational intelligence and neuroscience · 2022Article
- Imaging pathological tau in atypical parkinsonisms: A review.Clinical parkinsonism & related disorders · 2022Review
Corrections and comments
- Erratum issuedErratum.2019
Authors and funding
27 authors at 3 institutions in 2 countries.
Dean F WongSection of High Resolution Brain PET, Department of Radiology and Radiological Sciences and Department of Nuclear Medicine, Johns Hopkins University, Baltimore, Maryland dfwong@jhmi.edu edilio.borroni@roche.com.
Robert A ComleyPharma Research and Early Development, Hoffmann-La Roche, Basel, Switzerland.
Hiroto KuwabaraSection of High Resolution Brain PET, Department of Radiology and Radiological Sciences and Department of Nuclear Medicine, Johns Hopkins University, Baltimore, Maryland.
Paul B RosenbergDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, Maryland.
Susan M ResnickDepartment of Medicine, Johns Hopkins University, Baltimore, Maryland; and.
Susanne OstrowitzkiPharma Research and Early Development, Hoffmann-La Roche, Basel, Switzerland.
Cristina VozziPharma Research and Early Development, Hoffmann-La Roche, Basel, Switzerland.
Frank BoessPharma Research and Early Development, Hoffmann-La Roche, Basel, Switzerland.
Esther OhLab of Behavior and Neuroscience, NIH-NIA IRP, Baltimore, Maryland.
Constantine G LyketsosDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore, Maryland.
Michael HonerPharma Research and Early Development, Hoffmann-La Roche, Basel, Switzerland.
Luca GobbiPharma Research and Early Development, Hoffmann-La Roche, Basel, Switzerland.
Gregory KleinPharma Research and Early Development, Hoffmann-La Roche, Basel, Switzerland.
Noble GeorgeSection of High Resolution Brain PET, Department of Radiology and Radiological Sciences and Department of Nuclear Medicine, Johns Hopkins University, Baltimore, Maryland.
Lorena GapasinSection of High Resolution Brain PET, Department of Radiology and Radiological Sciences and Department of Nuclear Medicine, Johns Hopkins University, Baltimore, Maryland.
Kelly KitzmillerSection of High Resolution Brain PET, Department of Radiology and Radiological Sciences and Department of Nuclear Medicine, Johns Hopkins University, Baltimore, Maryland.
Josh RobertsSection of High Resolution Brain PET, Department of Radiology and Radiological Sciences and Department of Nuclear Medicine, Johns Hopkins University, Baltimore, Maryland.
Jeff SevignyPharma Research and Early Development, Hoffmann-La Roche, Basel, Switzerland.
Ayon NandiSection of High Resolution Brain PET, Department of Radiology and Radiological Sciences and Department of Nuclear Medicine, Johns Hopkins University, Baltimore, Maryland.
James BrasicSection of High Resolution Brain PET, Department of Radiology and Radiological Sciences and Department of Nuclear Medicine, Johns Hopkins University, Baltimore, Maryland.
Chakradhar MishraSection of High Resolution Brain PET, Department of Radiology and Radiological Sciences and Department of Nuclear Medicine, Johns Hopkins University, Baltimore, Maryland.
Madhav ThambisettyLab of Behavior and Neuroscience, NIH-NIA IRP, Baltimore, Maryland.
Abhay MogekarDepartment of Neurology, Johns Hopkins University, Baltimore, Maryland.
Anil MathurSection of High Resolution Brain PET, Department of Radiology and Radiological Sciences and Department of Nuclear Medicine, Johns Hopkins University, Baltimore, Maryland.
Marilyn AlbertDepartment of Neuroscience, Johns Hopkins University, Baltimore, Maryland.
Robert F DannalsSection of High Resolution Brain PET, Department of Radiology and Radiological Sciences and Department of Nuclear Medicine, Johns Hopkins University, Baltimore, Maryland.
Edilio BorroniPharma Research and Early Development, Hoffmann-La Roche, Basel, Switzerland.
Johns Hopkins University · USRoche (Switzerland) · CHNational Institute on Drug Abuse · US
Funding
'T V ASSESSMENT - MEMORY DISORDERED PATIENTS'P50AG005146 · NIA · JOHNS HOPKINS UNIVERSITY · PI ALBERT, MARILYN S. · 1985 to 2019
$37.6MNeuroimaging Predictors of Cognitive Decline, Impairment, and ResilienceZIAAG000191 · NIA · NATIONAL INSTITUTE ON AGING · PI FERRUCCI, LUIGI · 2009 to 2025
$26.4MUnderstanding mechanisms and seeking novel biomarkers in Alzheimer's diseaseZIAAG000200 · NIA · NATIONAL INSTITUTE ON AGING · PI RESNICK, SUSAN · 2013 to 2024
$12.2MTau PET in BLSA Participants: An Alzheimer's Disease BiomarkerZIAAG000341 · NIA · NATIONAL INSTITUTE ON AGING · PI RESNICK, SUSAN · 2017 to 2024
$6.7MTraining for Clinician Scientists in Imaging ResearchT32EB006351 · NIBIB · JOHNS HOPKINS UNIVERSITY · PI POMPER, MARTIN G · 2006 to 2022
$4.0MNIA NIH HHS P50 AG005146NIBIB NIH HHS T32 EB006351
Abstract
PubMed holds no abstract for this paper.
Indexed as
RadiopharmaceuticalsAdultAgedAlzheimer DiseaseBrainBrain MappingCarbon RadioisotopesCase-Control StudiesFemaleFluorine RadioisotopesHumansMaleMiddle AgedPositron-Emission TomographyRadiation DosageRadioligand AssayCarbon-11Carbon RadioisotopesFluorine-18Fluorine RadioisotopesMAPT protein, humanRadiopharmaceuticalstau ProteinsAlzheimer diseasemolecular imagingnovel radiotracersPETradiotracer developmenttau
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.